Edgewise Therapeutics (EWTX) EBITDA (2020 - 2026)

Edgewise Therapeutics has disclosed EBITDA across 7 years of filings, most recently posting -$49.9 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$49.9 million, down 22.36% year-over-year; the trailing twelve-month figure through Mar 2026 was -$176.7 million (down 21.98% YoY), and the FY2025 annual result was -$167.5 million, down 25.5% from the prior year.
• EBITDA came in at -$49.9 million for Q1 2026 at Edgewise Therapeutics, up from -$50.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$16.1 million in Q1 2022 to a low of -$50.2 million in Q4 2025.
• The 5-year median for EBITDA is -$29.6 million (2023), against an average of -$30.5 million.
• Across the five-year window, EBITDA tumbled 134.07% in 2022 and slipped 14.59% in 2025, its largest moves.
• Edgewise Therapeutics' EBITDA stood at -$18.6 million in 2022, then sank by 59.32% to -$29.6 million in 2023, then sank by 36.03% to -$40.3 million in 2024, then decreased by 24.69% to -$50.2 million in 2025, then climbed by 0.59% to -$49.9 million in 2026.
• The last three EBITDA figures came in at -$49.9 million (Q1 2026), -$50.2 million (Q4 2025), and -$40.2 million (Q3 2025), per Business Quant data.